Cargando…
Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation
Anti-osteoporotic activity of a blocker of the ubiquitin-proteasome system, bortezomib, has known to be achieved by directly opposed action in increased bone formation by osteoblasts and in decreased bone destruction by osteoclasts. However, the mechanisms underlying the proteasome blocker inhibitio...
Autores principales: | Lee, Kyunghee, Kim, Mi Yeong, Ahn, Heejin, Kim, Han-Sung, Shin, Hong-In, Jeong, Daewon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666736/ https://www.ncbi.nlm.nih.gov/pubmed/28946669 http://dx.doi.org/10.3390/ijms18102054 |
Ejemplares similares
-
Specific targeting of PKCδ suppresses osteoclast differentiation by accelerating proteolysis of membrane-bound macrophage colony-stimulating factor receptor
por: Kim, Mi Yeong, et al.
Publicado: (2019) -
Selective Regulation of MAPK Signaling Mediates RANKL-dependent Osteoclast Differentiation
por: Lee, Kyunghee, et al.
Publicado: (2016) -
Caveolin-1 regulates osteoclast differentiation by suppressing cFms degradation
por: Lee, Yong Deok, et al.
Publicado: (2015) -
Pisidium coreanum Inhibits Multinucleated Osteoclast Formation and Prevents Estrogen-Deficient Osteoporosis
por: Choi, Mun Hwan, et al.
Publicado: (2019) -
Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation
por: Lindsten, Kristina, et al.
Publicado: (2002)